<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670576</url>
  </required_header>
  <id_info>
    <org_study_id>18014</org_study_id>
    <nct_id>NCT03670576</nct_id>
  </id_info>
  <brief_title>It's Not JUST Idiopathic Pulmonary Fibrosis Study</brief_title>
  <acronym>INJUSTIS</acronym>
  <official_title>It's Not JUST Idiopathic Pulmonary Fibrosis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of progression of fibrosis in ILD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aims of this study are&#xD;
&#xD;
        -  Identify biomarkers and gene expression profiles that determine progressive fibrotic&#xD;
           lung disease regardless of aetiology&#xD;
&#xD;
        -  To prospectively assess biomarkers which predict progressive fibrosis in patients with&#xD;
           fibrosing lung disease of alternate aetiology, including RA-UIP, Asbestosis, Chronic&#xD;
           Hypersensitivity Pneumonitis and Unclassifiable fibrotic lung disease&#xD;
&#xD;
        -  Investigate genetic associations and epigenetic modifications which affect fibrotic&#xD;
           disease severity and progression&#xD;
&#xD;
        -  Prospectively evaluate longitudinal disease behaviour in patients with non IPF-fibrotic&#xD;
           lung diseases with a view to developing composite clinical end-points for subsequent use&#xD;
           in intervention studies in patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2018</start_date>
  <completion_date type="Anticipated">November 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>Within 12 months</time_frame>
    <description>Disease progression defined as &gt;10% relative decline in FVC (using either hospital spirometry or home hand held spirometry) or death within 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>10 years</time_frame>
    <description>All patients will be tagged at the central NHS registry in order to provide mortality data. For this reason we will need to keep our datasets active for up to 10 years to allow a complete mortality analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum and Plasma Biomarkers</measure>
    <time_frame>Baseline, 3 months, 12 months, 24 months</time_frame>
    <description>SPD, MUC16, CA199, Nordic Neoepitopes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>DLco</measure>
    <time_frame>Baseline, 3 months, 12 months, 24 months</time_frame>
    <description>Diffusing Capacity of the Lung for Carbon Monoxide</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Questionnaires</measure>
    <time_frame>Baseline, 3 months, 12 months, 24 months.</time_frame>
    <description>Assessment of how the patients well-being may be affected over time by their interstitial lung disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Domicillary Spirometry</measure>
    <time_frame>Daily for the first 3 months of study then at 2 week periods around time of planned follow up</time_frame>
    <description>Change in home handheld spirometry values from baseline to 12 weeks</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optional Bronchoscopy</intervention_name>
    <description>Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life Questionnaires</intervention_name>
    <description>MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Samples for Biomarkers</intervention_name>
    <description>a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home Hand Held Spirometry</intervention_name>
    <description>Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (Serum, Plasma) Bronchoscopy Biopsy Samples (Optional)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from ILD and IPF clinics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male or female aged â‰¥ 18 years old&#xD;
&#xD;
          -  Able and willing to give written informed consent&#xD;
&#xD;
          -  Recently diagnosed [defined as diagnostic CT scan or surgical lung biopsy (if&#xD;
             applicable) &gt;1st May 2017]&#xD;
&#xD;
          -  An MDT diagnosis of fibrotic interstitial lung disease (reticulation, traction +/-&#xD;
             honeycombing)&#xD;
&#xD;
        Sub Groups&#xD;
&#xD;
          -  Rheumatoid arthritis (rheumatologist diagnosed with anti-CCP antibodies and/or&#xD;
             Rheumatoid Factor positive)&#xD;
&#xD;
          -  Asbestosis (appropriate occupational history and radiological evidence of asbestos&#xD;
             exposure)&#xD;
&#xD;
          -  Chronic HP in accordance with consensus criteria (appropriate exposure history,&#xD;
             radiological features +/- avian and fungal precipitins)&#xD;
&#xD;
          -  Unclassifiable fibrotic lung disease (fibrotic lung disease otherwise unclassifiable&#xD;
             despite extensive clinical and radiological examination)&#xD;
&#xD;
          -  IPF in accordance with consensus criteria (ATS/ERS/JRS/ALAT guidelines) as controls&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participating in an interventional clinic trial&#xD;
&#xD;
          -  Asymptomatic Interstitial Lung Abnormalities (ILA) and normal lung function.&#xD;
&#xD;
          -  Change in clinical phenotype from initial radiological diagnosis to screening&#xD;
&#xD;
          -  Acute Hypersensitivity Pneumonitis.&#xD;
&#xD;
          -  Participants who do not possess a smartphone or have a valid email address (necessary&#xD;
             for the home FVC readings)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prof Gisli Jenkins</last_name>
    <phone>0115 8231711</phone>
    <email>gisli.jenkins@nottingham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucy Howard</last_name>
    <phone>01158231326</phone>
    <email>lucy.howard@nottingham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queens Hospital Burton</name>
      <address>
        <city>Burton on Trent</city>
        <state>Derbyshire</state>
        <zip>DE15 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Uttam Nanda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings Mill Hospital</name>
      <address>
        <city>Mansfield</city>
        <state>Nottingham</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal United Hospitals Bath NHS Trust</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Noeleen Foley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Gareth Walters</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Thomas Bongers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital North Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Huzaifa Adamali</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Srividya Narayan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Lines</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Lisa Vincent-Smith</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Siva Mahendran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Georges Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Raminder Aul</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Zoe Borrill</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Nazia Chaudhuri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sarah Wiscombe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northumbria Healthcare NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Laura McKay</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Gisli Jenkins</last_name>
      <phone>0115 8231711</phone>
      <email>gisli.jenkins@nottingham.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Howard</last_name>
      <phone>0115 8231326</phone>
      <email>lucy.howard@nottingham.ac.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Steve Bianchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <zip>NE34 0PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Liz Fuller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Graham Miller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taunton and Somerset NHS Foundation Trust</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr James Davidson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Albert and Edward Infirmary</name>
      <address>
        <city>Wigan</city>
        <zip>WN1 2NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Abdul Ashish</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ahmed Fahim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Stephen O'Hickey</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

